Niagen Bioscience, Inc. — Director's Dealing 2012

Feb 9, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC.OB)
CIK: 0001386570
Period of Report: 2012-02-07

Reporting Person: Himmel Jeffrey (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-02-07	Common Stock, Par Value $0.001 per share	A	100000	$0.00	Acquired	100000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-02-07	Employee Stock Option (Right to Buy)	$0.89	A	1000000	Acquired	2017-02-07	Common Stock (1000000)	Direct
2012-02-07	Employee Stock Option (Right to Buy)	$0.89	A	1000000	Acquired	2017-02-07	Common Stock (1000000)	Direct

Footnotes

F1: Such Options are subject to the following vesting schedule: one third shall vest and become exercisable on the first anniversary of the grant, and the remaining two thirds of the Options shall vest monthly over the twenty-four months following the first anniversary of the grant date.